|
🐜
|
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
25 auth.
B. Paiva,
M. Vidriales,
J. Cerveró,
G. Mateo,
J. Pérez,
M. Montalbán,
A. Sureda,
L. Montejano,
N. Gutiérrez,
A. Garcia de Coca,
N. de Las Heras,
M. Mateos,
M. López-Berges,
R. García-Boyero,
J. Galende,
...
J. Hernández,
L. Palomera,
D. Carrera,
R. Martínez,
J. de la Rubia,
Alejandro Martín,
J. Bladé,
J. Lahuerta,
A. Órfão,
J. S. San Miguel
|
8 |
2008 |
8
🐜
|
|
🐜
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
25 auth.
M. Mateos,
J. Hernández,
M. Hernandez,
N. Gutiérrez,
L. Palomera,
M. Fuertes,
J. Díaz-Mediavilla,
J. Lahuerta,
J. de la Rubia,
M. Terol,
A. Sureda,
J. Bargay,
P. Ribas,
F. de Arriba,
A. Alegre,
...
A. Oriol,
D. Carrera,
J. García-Laraña,
R. García-Sanz,
J. Bladé,
F. Prósper,
G. Mateo,
D. Esseltine,
H. V. D. van de Velde,
J. S. San Miguel
|
8 |
2006 |
8
🐜
|
|
🐜
|
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
20 auth.
J. Lahuerta,
M. Mateos,
J. Martínez-López,
L. Rosiñol,
A. Sureda,
J. de la Rubia,
J. García-Laraña,
R. Martínez-Martínez,
M. Hernández-Garcia,
D. Carrera,
...
J. Besalduch,
F. de Arriba,
J. Ribera,
L. Escoda,
Belén Hernández-Ruiz,
J. García-Frade,
Concepción Rivas-González,
A. Alegre,
J. Bladé,
J. S. San Miguel
|
8 |
2008 |
8
🐜
|
|
🐜
|
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
17 auth.
L. Rosiñol,
J. Pérez-Simón,
A. Sureda,
J. de la Rubia,
F. de Arriba,
J. Lahuerta,
José D. González,
J. Díaz-Mediavilla,
B. Hernández,
J. García-Frade,
...
D. Carrera,
A. León,
M. Hernandez,
P. F. Abellán,
J. Bergua,
J. S. San Miguel,
J. Bladé
|
8 |
2008 |
8
🐜
|
|
🐜
|
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
17 auth.
D. Valcárcel,
R. Martino,
D. Caballero,
Jesús Martín,
C. Ferrá,
J. Nieto,
A. Sampol,
M. Bernal,
J. Piñana,
L. Vázquez,
...
J. Ribera,
J. Besalduch,
J. Moraleda,
D. Carrera,
M. Brunet,
J. Pérez-Simón,
J. Sierra
|
7 |
2008 |
7
🐜
|
|
🐜
|
Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.
26 auth.
A. Sureda,
R. Arranz,
A. Iriondo,
E. Carreras,
J. Lahuerta,
J. Garcia-conde,
I. Jarque,
M. Caballero,
C. Ferrá,
A. López,
J. García-Laraña,
R. Cabrera,
D. Carrera,
M. D. Ruiz-Romero,
A. León,
...
J. Rifón,
J. Díaz-Mediavilla,
R. Mataix,
M. Morey,
J. Moraleda,
A. Altés,
A. López-Guillermo,
J. Serna,
J. Fernández‐Rañada,
J. Sierra,
E. Conde
|
7 |
2001 |
7
🐜
|
|
🐜
|
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.
30 auth.
A. Sureda,
M. Constans,
A. Iriondo,
R. Arranz,
M. Caballero,
M. Vidal,
J. Petit,
Aurelio López,
J. Lahuerta,
E. Carreras,
J. Garcia-conde,
J. García-Laraña,
R. Cabrera,
I. Jarque,
D. Carrera,
...
J. C. García-Ruiz,
Marién Pascual,
J. Rifón,
J. Moraleda,
K. Perez‐Equiza,
C. Albó,
J. Díaz-Mediavilla,
A. Torres,
P. Torres,
J. Besalduch,
J. Marín,
M. Mateos,
J. Fernández-Rañada,
J. Sierra,
E. Conde
|
7 |
2005 |
7
🐜
|
|
🐜
|
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
18 auth.
N. Gutiérrez,
Marta Castellanos,
M. Martín,
M. Mateos,
J. Hernandez,
M. Fernández,
D. Carrera,
L. Rosiñol,
Josep-Maria Ribera,
José M. Ojanguren,
...
L. Palomera,
S. Gardella,
L. Escoda,
J. Hernández-Boluda,
J. Bello,
J. Rubia,
J. Lahuerta,
J. Miguel
|
7 |
2007 |
7
🐜
|
|
🐜
|
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
43 auth.
J. S. Miguel,
J. Lahuerta,
Ramón García-Sanz,
A. Alegre,
J. Bladé,
R. Martínez,
J. García-Laraña,
J. Rubia,
A. Sureda,
María Jesús Vidal,
A. Escudero,
E. Pérez-Esquiza,
E. Conde,
J. C. García-Ruiz,
Rafael Cabrera,
...
D. Caballero,
J. Moraleda,
A. León,
J. Besalduch,
M. Hernández,
J. Rifón,
F. Hernández,
Carlos Solano,
L. Palomera,
R. Parody,
Juan Gonzalez,
R. Mataix,
J. Maldonado,
J. Constela,
D. Carrera,
J. Bello,
J. M. D. Pablos,
J. Pérez-Simón,
Juan Pablo Torres,
J. Olanguren,
E. Prieto,
G. Acebede,
M. Peñarrubia,
P. Torres,
J. Díez-Martín,
Ana Rivas,
Jaime Merino Sánchez,
J. Díaz-Mediavilla
|
6 |
2000 |
6
🐜
|
|
🐜
|
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
20 auth.
J. Lahuerta,
M. Mateos,
J. Martínez-López,
C. Grande,
J. de la Rubia,
L. Rosiñol,
A. Sureda,
J. García-Laraña,
J. Díaz-Mediavilla,
M. Hernández-Garcia,
...
D. Carrera,
J. Besalduch,
F. de Arriba,
A. Oriol,
L. Escoda,
J. García-Frade,
Concepción Rivas-González,
A. Alegre,
J. Bladé,
J. S. San Miguel
|
6 |
2010 |
6
🐜
|
|
🐜
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
25 auth.
M. Mateos,
J. Hernández,
M. Hernandez,
N. Gutiérrez,
L. Palomera,
M. Fuertes,
P. García-Sánchez,
J. Lahuerta,
J. de la Rubia,
M. Terol,
A. Sureda,
J. Bargay,
P. Ribas,
A. Alegre,
F. de Arriba,
...
A. Oriol,
D. Carrera,
J. García-Laraña,
R. García-Sanz,
J. Bladé,
F. Prósper,
G. Mateo,
D. Esseltine,
H. V. D. van de Velde,
J. S. San Miguel
|
6 |
2008 |
6
🐜
|
